Minneapolis Heart Institute Foundation® researchers find potential value in the use of the MitraClip for HCM patients at unacceptable surgical risk.
Minneapolis, MN – March 30, 2016 – Few therapeutic options exist for patients with severe heart failure due to obstructive hypertrophic cardiomyopathy (HCM) who are at unacceptable surgical risk. HCM is an inherited condition in which the cells of the heart muscle become enlarged, causing the walls of the ventricles to thicken. Sometimes this thickening may block blood flow out of the ventricle, which is called obstructive hypertrophic cardiomyopathy. HCM can lead to increased blood pressure and can lead to heart arrhythmias. Surgery is usually the answer, but the open heart procedures are not recommended for high surgical risk patients.
Researchers at the Minneapolis Heart Institute Foundation® (MHIF) considered the possibility that using MitraClip® in a percutaneous procedure (not involving opening the chest) could be an effective technique in reducing systolic anterior motion of the valve and associated mitral regurgitation in obstructive HCM, thereby providing an alternate strategy for relief of heart failure symptoms. While use of the MitraClip therapy for HCM has been reported previously in a single patient, the MHIF study is the first experience worldwide with percutaneous mitral valve plication employed as an initial interventional therapy for the management of LV outflow tract obstruction in HCM.
Six patients with severe obstructive HCM, who were judged as too high risk for surgery, were treated with the percutaneous MitraClip procedure. One patient suffered cardiac tamponade and the procedure was halted. The five remaining patients received the MitraClip, and all were found to have improved cardiac output after the procedure. In clinical follow-up, all patients reported symptom improvement by at least one NYHA class, and further intervention was not required.
About the Minneapolis Heart Institute Foundation®
The Minneapolis Heart Institute Foundation (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, it is dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.
- Scientific Innovation and Research — MHIF is a recognized research leader in the broadest range of cardiovascular medicine and population health initiatives. Each year MHIF leads more than 175 active research projects and publishes more than 120 peer-reviewed studies. Cardiologists, hospitals and communities around the world adopt MHIF protocols to save lives, improve care and create healthier living opportunities.
- Education and Outreach — MHIF provides more than 10,000 hours of education each year putting its research into practice to improve outcomes. And, MHIF leads cutting-edge, transformative population health research to connect, engage, inform and empower individuals and communities to improve their health.
The Minneapolis Heart Institute Foundation’s work is funded by generous donors and sponsors and supports research initiatives of Minneapolis Heart Institute® at Abbott Northwestern Hospital.
Minneapolis Heart Institute® physicians provide care for patients at Abbott Northwestern Hospital in Minneapolis and at 38 community sites across Minnesota and western Wisconsin.
About Abbott Laboratories’ MitraClip
The MitraClip device is a small clip that is attached to the mitral valve. It treats mitral regurgitation by allowing the valve to close more completely, helping to restore normal blood flow through the heart, without the need for opening up the chest or temporarily stopping the heart. Instead, doctors access the mitral valve with a thin tube (called a catheter) that is guided through a vein in the leg to reach the heart. Patients who were studied one year after the MitraClip procedure continued to experience improvement in their quality of life and ability to perform day-to-day tasks. They also had fewer visits to the hospital for complications due to heart failure.